Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Persistent cognitive dysfunction after traumatic brain injury: A dopamine hypothesis Bales JW; Wagner AK; Kline AE; Dixon CENeurosci Biobehav Rev 2009[Jul]; 33 (7): 981-1003Traumatic brain injury (TBI) represents a significant cause of death and disability in industrialized countries. Of particular importance to patients the chronic effect that TBI has on cognitive function. Therapeutic strategies have been difficult to evaluate because of the complexity of injuries and variety of patient presentations within a TBI population. However, pharmacotherapies targeting dopamine (DA) have consistently shown benefits in attention, behavioral outcome, executive function, and memory. Still it remains unclear what aspect of TBI pathology is targeted by DA therapies and what time-course of treatment is most beneficial for patient outcomes. Fortunately, ongoing research in animal models has begun to elucidate the pathophysiology of DA alterations after TBI. The purpose of this review is to discuss clinical and experimental research examining DAergic therapies after TBI, which will in turn elucidate the importance of DA for cognitive function/dysfunction after TBI as well as highlight the areas that require further study.|*Models, Neurological[MESH]|Animals[MESH]|Brain Injuries/drug therapy/*physiopathology[MESH]|Brain/drug effects/physiopathology[MESH]|Cognition Disorders/drug therapy/*physiopathology[MESH]|Cognition/physiology[MESH]|Dopamine Agonists/pharmacology[MESH]|Dopamine Antagonists/adverse effects/pharmacology[MESH]|Dopamine/*metabolism[MESH]|Humans[MESH] |